A Look at the Immunotherapy Pipeline for Multiple Myeloma

This article was originally published on Docwire News

Nina Shah, MD, an associate professor in the Department of Medicine at the University of California, San Francisco, discusses immunotherapy agents in the pipeline for multiple myeloma (MM) and how the potential approval of these agents could change the treatment landscape and advance combination therapy.

Watch part 1 of the interview with Dr. Shah where she discusses novel immunotherapy agents for MM and their unique targets.

Watch part 2 of the interview with Dr. Shah, where she talks about two new MM agents granted priority review by the FDA.

To continue reading this article on Docwire News